190 related articles for article (PubMed ID: 8233270)
1. Macrophage colony-stimulating factor as a tumor marker for epithelial ovarian cancer.
Suzuki M; Ohwada M; Aida I; Tamada T; Hanamura T; Nagatomo M
Obstet Gynecol; 1993 Dec; 82(6):946-50. PubMed ID: 8233270
[TBL] [Abstract][Full Text] [Related]
2. [Macrophage-colony stimulating factor and ovarian cancer].
Menditto A; Piscittelli V; Cassese F; Balbi GC; Balbi C; Cardone A
Minerva Ginecol; 1999; 51(7-8):261-4. PubMed ID: 10536419
[TBL] [Abstract][Full Text] [Related]
3. [The plasma levels and diagnostic utility of granulocyte colony stimulating factor (G-CSF) and macrophage - colony stimulating factor (M-CSF) in ovarian cancer patients].
ławicki S; Czygier M; Gacuta-Szumarska E; Knapp P; Szmitkowski M
Pol Merkur Lekarski; 2006 Nov; 21(125):465-8. PubMed ID: 17345841
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of combined use of macrophage colony-stimulating factor and squamous cell carcinoma antigen as a selective diagnostic marker for squamous cell carcinoma arising in mature cystic teratoma of the ovary.
Suzuki M; Tamura N; Kobayashi H; Ohwada M; Terao T; Sato I
Gynecol Oncol; 2000 Jun; 77(3):405-9. PubMed ID: 10831350
[TBL] [Abstract][Full Text] [Related]
5. Macrophage colony-stimulating factor as a marker for malignant germ cell tumors of the ovary.
Suzuki M; Kobayashi H; Ohwada M; Terao T; Sato I
Gynecol Oncol; 1998 Jan; 68(1):35-7. PubMed ID: 9454657
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
[TBL] [Abstract][Full Text] [Related]
7. Serum sErbB1 and epidermal growth factor levels as tumor biomarkers in women with stage III or IV epithelial ovarian cancer.
Baron AT; Lafky JM; Boardman CH; Balasubramaniam S; Suman VJ; Podratz KC; Maihle NJ
Cancer Epidemiol Biomarkers Prev; 1999 Feb; 8(2):129-37. PubMed ID: 10067810
[TBL] [Abstract][Full Text] [Related]
8. [Study on serum vascular endothelial growth factor level in ovarian malignant tumors].
Li L; Wang LM; Zhang W; Zhang JQ; Song HL; Yao DS; Tang Y; Chen XQ; Yang ZH
Zhonghua Fu Chan Ke Za Zhi; 2003 Feb; 38(2):72-6. PubMed ID: 12783691
[TBL] [Abstract][Full Text] [Related]
9. Serum macrophage-colony stimulating factor levels in colorectal cancer patients correlate with lymph node metastasis and poor prognosis.
Mroczko B; Groblewska M; Wereszczyńska-Siemiatkowska U; Okulczyk B; Kedra B; Łaszewicz W; Dabrowski A; Szmitkowski M
Clin Chim Acta; 2007 May; 380(1-2):208-12. PubMed ID: 17368603
[TBL] [Abstract][Full Text] [Related]
10. The role of colony-stimulating factor 1 and its receptor in the etiopathogenesis of endometrial adenocarcinoma.
Smith HO; Anderson PS; Kuo DY; Goldberg GL; DeVictoria CL; Boocock CA; Jones JG; Runowicz CD; Stanley ER; Pollard JW
Clin Cancer Res; 1995 Mar; 1(3):313-25. PubMed ID: 9815987
[TBL] [Abstract][Full Text] [Related]
11. Serum macrophage colony-stimulating factor (M-CSF) levels in patients with epithelial ovarian cancer.
Gadducci A; Ferdeghini M; Castellani C; Annicchiarico C; Prontera C; Facchini V; Bianchi R; Genazzani AR
Gynecol Oncol; 1998 Jul; 70(1):111-4. PubMed ID: 9698485
[TBL] [Abstract][Full Text] [Related]
12. Macrophage colony-stimulating factor as a tumor marker for epithelial ovarian cancer.
Fuith LC; Czarnecki M; Wachter H; Fuchs D
Obstet Gynecol; 1994 May; 83(5 Pt 1):801. PubMed ID: 8164949
[No Abstract] [Full Text] [Related]
13. [The plasma levels of granulocyte-colony stimulating factor and granulocyte-macrophage colony stimulating factor in breast cancer patients].
Ławicki S; Czygier M; Omyła J; Bedkowska E; Szmitkowski M
Pol Merkur Lekarski; 2007 Oct; 23(136):259-63. PubMed ID: 18293847
[TBL] [Abstract][Full Text] [Related]
14. The pretreatment plasma level and diagnostic utility of M-CSF in benign breast tumor and breast cancer patients.
Ławicki S; Szmitkowski M; Wojtukiewicz M
Clin Chim Acta; 2006 Sep; 371(1-2):112-6. PubMed ID: 16631152
[TBL] [Abstract][Full Text] [Related]
15. Detection of serum transforming growth factor-alpha in patients of primary epithelial ovarian cancers by enzyme immunoassay.
Chien CH; Huang CC; Lin YH; Shen J; Chow SN
Gynecol Oncol; 1997 Sep; 66(3):405-10. PubMed ID: 9299253
[TBL] [Abstract][Full Text] [Related]
16. Monocyte chemoattractant protein-1 serum levels in ovarian cancer patients.
Hefler L; Tempfer C; Heinze G; Mayerhofer K; Breitenecker G; Leodolter S; Reinthaller A; Kainz C
Br J Cancer; 1999 Nov; 81(5):855-9. PubMed ID: 10555758
[TBL] [Abstract][Full Text] [Related]
17. Utility of osteopontin as a biomarker in recurrent epithelial ovarian cancer.
Brakora KA; Lee H; Yusuf R; Sullivan L; Harris A; Colella T; Seiden MV
Gynecol Oncol; 2004 May; 93(2):361-5. PubMed ID: 15099946
[TBL] [Abstract][Full Text] [Related]
18. [The CA-125 tumor marker in epithelial ovarian cancers of stage I].
Nagele F; Vavra N; Kurz C; Sevelda P
Wien Klin Wochenschr; 1993; 105(20):585-8. PubMed ID: 8259686
[TBL] [Abstract][Full Text] [Related]
19. [Serum level and expression of vascular epithelial growth factor in ovarian epithelial carcinoma].
Sun LX; Wu Y; Han HQ; Wang QH
Ai Zheng; 2003 Jan; 22(1):58-61. PubMed ID: 12561438
[TBL] [Abstract][Full Text] [Related]
20. Strategies for improving the specificity of screening for ovarian cancer with tumor-associated antigens CA 125, CA 15-3, and TAG 72.3.
Jacobs IJ; Oram DH; Bast RC
Obstet Gynecol; 1992 Sep; 80(3 Pt 1):396-9. PubMed ID: 1495694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
